Last week, BioBuzz, in partnership with EMINENT Life Sciences, kicked off its highly anticipated new event series, “Off the Record,” aiming to delve into the most pressing challenges and exciting opportunities shaping the Mid-Atlantic’s burgeoning life sciences sectors.
The inaugural event took place at the EMINENT Life Sciences Campus in Frederick, Maryland, a dynamic hub that houses both CIAN Diagnostics and EMINENT Life Sciences. CIAN boasts a cutting-edge 75,000 sq. ft. CLIA-accredited laboratory, providing vital infrastructure for clinical testing and research. Adjacent to it, EMINENT offers an equally impressive 75,000 sq. ft. GMP-compliant manufacturing space designed to accelerate the production of therapeutics at scale.
“In a market where capital is tight, timelines are stretched, and the pressure to deliver is higher than ever, we can’t just innovate, we need to do it smarter, faster, and more sustainably, together,” said Chris Frew, CEO of BioBuzz Networks. “We’re thrilled to explore that in this quarterly series with unfiltered perspectives from biotech leaders and regional changemakers.”
The evening’s program was anchored by three engaging fireside chats, each spotlighting critical areas of growth. Panels explored cutting-edge advances in cell and gene therapy, innovations in biomanufacturing, and the evolving role of dual-use military health technologies.
Together, these discussions provided attendees with a unique window into how the region is not only building companies but also cultivating the capabilities that will drive long-term industry leadership.
The event gathered a diverse group of life sciences leaders, entrepreneurs, investors, and researchers, fostering connections and conversations designed to fuel collaboration across sectors. Attendees left with a deeper appreciation of the challenges ahead and the promising paths Maryland’s life sciences community is charting to overcome them.
Here are just a few of the many takeaways.
Cell & Gene Therapy: From Rare to Routine
The evening opened with a forward-looking discussion between Dr. Patrick Hanley, Chief & Director, Cellular Therapy Program, Children’s National, and Dr. Emily English, COO, Cartesian Therapeutics, who reflected on the evolution of cell and gene therapies from rare-disease interventions to more widely applicable treatments.
“In the first panel [with Emily and Patrick] The cell therapies they’re developing—and the challenges they face in making them more accessible—highlight just how vital and complex this work is. It was inspiring to hear how impactful their innovations already are.” – Jake Jakubek,
They explored the complementary roles of academic and commercial models, highlighting how both are essential to advancing the field. Their conversation underscored the need for scalable delivery systems, stronger infrastructure, and continued regulatory collaboration to expand patient access to these life-changing therapies.
Biomanufacturing as a Growth Engine
In the second fireside chat, Kelly Schulz, CEO, Maryland Tech Council, and Dr. Tim Fouts, CSO, ABL, explored how Maryland can strengthen its position as a national leader in biomanufacturing.
Their discussion centered on the need to move beyond innovation and into scalable infrastructure, workforce development, and industry collaboration. Together, they highlighted the importance of investing in manufacturing capabilities that can support the region’s growing pipeline of scientific breakthroughs.
Dual-Use Technologies: Military Medicine Meets Market Innovation
The final fireside chat brought together Stephen Dalal, VP, US Research & Development, The Henry M. Jackson Foundation for the Advancement of Military Medicine, and Dr. Mustafa Al-Adhami, CEO, Astek Diagnostics, to discuss the intersection of military and civilian health innovation.
The discussion explored how life science startups can strategically align with defense priorities while maintaining commercial relevance. From diagnostics to deployment strategies, the conversation emphasized how thoughtful partnerships and infrastructure support can open new doors for early-stage companies in the region.
A Common Thread: Infrastructure, Access, and Storytelling
Even with all the diversity of topics, three themes echoed across all conversations:
- Infrastructure investment is overdue. Whether in biomanufacturing, cell therapy, or dual-use tech, speakers agreed that physical space, production capabilities, and talent pipelines remain bottlenecks—and opportunities—for the region.
- Regulatory bodies are partners, not adversaries. Panelists from both academia and industry noted that the FDA and DoD offer more support than many innovators realize, especially when startups engage early and communicate clearly.
- Scientific innovation alone isn’t enough—science needs storytellers. Panelists consistently highlighted the importance of communicating not just what technologies do, but why they matter. Whether advancing new therapies, building infrastructure, or forging strategic partnerships, it was clear that compelling narratives play a vital role in earning trust, securing investment, and inspiring collaboration.
“Growth isn’t just [Em]inent—it’s ours to claim,” said Katherine Mooney during closing remarks. Judging by the energy in the room, the Mid-Atlantic is well on its way.
